Clinical studies

Pratteln, Switzerland, February 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of the article “Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy” in the journal Neurology [2]. The publication reports the results of 48 weeks of treatment with vamorolone in patients with DMD in the VISION-DMD study. It confirms the long-term efficacy and safety profile, as well as the generally good tolerability, of vamorolone, consistent with the study results after 24 weeks previously published in JAMA Neurology [3]. Santhera announces publication of efficacy, safety, and tolerability data of vamorolone (AGAMREE®) in patients with Duchenne muscular dystrophy in Neurology

STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the Phase III clinical trial, Flamingo-01. Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

The US Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. "This approval provides patients with the first-ever treatment option for severe frostbite," said Norman Stockbridge, MD, Ph.D., director of the Division of Cardiology and Nephrology in the FDA's Center for Drug Evaluation and Research. Having this new option provides physicians with a tool that will help prevent the lifechanging amputation of one's frostbitten fingers or toes. Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation. Iloprost, the active ingredient in Aurlumyn, is a vasodilator (a drug that opens blood vessels) and…